Sagimet Biosciences Q1 2026 Earnings Report

Sagimet Biosciences EPS Results

• Actual EPS: -$0.33
• Consensus EPS: -$0.39
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Sagimet Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sagimet Biosciences Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 12, 2026
• Conference Call Time: 7:00AM ET

Sagimet Biosciences (NASDAQ:SGMT) (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes. The company’s research platform leverages a proprietary chemokine-targeted approach to address underlying disease mechanisms rather than solely treating symptoms. By focusing on the molecular cues that recruit pro-fibrotic cells, Sagimet aims to develop therapies with the potential for disease modification in conditions that today have limited treatment options.

Headquartered in the San Francisco Bay Area, Sagimet Biosciences operates research and development facilities that support both in-house discovery and collaborative initiatives with academic and industry partners. Since its formation in 2020, the company has built a team of scientists and clinicians with expertise in fibrosis biology, protein engineering and translational medicine. This multidisciplinary organization is structured to accelerate candidates from early discovery through proof-of-concept studies.

Sagimet’s leadership team is led by President and Chief Executive Officer Dr. Steven Landis, a recognized expert in fibrotic disease research and a co-founder of the company’s predecessor, Cirius Therapeutics. Under Dr. Landis’s guidance, Sagimet has established a clear clinical development plan for CM-101 and is advancing strategic collaborations to expand its pipeline. The company’s strategic vision is centered on delivering first-in-class and best-in-class therapies for patients with high-unmet-need fibrotic disorders.